 Shares of Myovant surged as much as 35 to 30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prostate cancer patients. The drug, called Orgovyx, was approved by the FDA on December 18 for the treatment of adult patients with advanced prostate cancer. Myovant is also working on a relugolix combination tablet that could treat patients with endometriosis and uterine fibroids. That tablet is still awaiting FDA approval. We are thrilled to partner with Pfizer to unlock the full potential of ORGOVYX in advanced prostate cancer and relugolix combination tablet in uterine fibroids and endometriosis, advancing our mission to redefine care for women and for men, said Lynn Seely, Myovant CEO, in an announcement. This transformative collaboration will significantly strengthen the upcoming launch of ORGOVYX and the potential launches of relugolix combination tablet in womens health, while substantially enhancing our financial position and enabling us to expand our pipeline of potential new medicines. Read more: Wall Streets biggest firms are warning that these 8 things could crash the stock markets party in 2021 